Analysts Expect ContraFect Corp (CFRX) Will Post Earnings of -$0.10 Per Share

Equities research analysts expect ContraFect Corp (NASDAQ:CFRX) to announce ($0.10) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for ContraFect’s earnings, with estimates ranging from ($0.11) to ($0.09). ContraFect reported earnings of ($0.09) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 11.1%. The firm is scheduled to issue its next quarterly earnings report on Thursday, May 9th.

According to Zacks, analysts expect that ContraFect will report full-year earnings of ($0.36) per share for the current fiscal year, with EPS estimates ranging from ($0.43) to ($0.31). For the next financial year, analysts anticipate that the business will report earnings of ($0.44) per share, with EPS estimates ranging from ($0.52) to ($0.36). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for ContraFect.

ContraFect (NASDAQ:CFRX) last announced its quarterly earnings results on Thursday, March 14th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.17.

Shares of NASDAQ:CFRX traded down $0.01 during trading on Tuesday, reaching $0.56. The stock had a trading volume of 100 shares, compared to its average volume of 1,993,187. ContraFect has a 52 week low of $0.35 and a 52 week high of $2.93. The firm has a market cap of $47.84 million, a P/E ratio of -1.51 and a beta of -0.35.

Several large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its stake in ContraFect by 108.1% during the third quarter. JPMorgan Chase & Co. now owns 167,182 shares of the biotechnology company’s stock worth $346,000 after acquiring an additional 86,848 shares in the last quarter. Renaissance Technologies LLC boosted its stake in ContraFect by 109.8% during the third quarter. Renaissance Technologies LLC now owns 420,700 shares of the biotechnology company’s stock worth $871,000 after acquiring an additional 220,200 shares in the last quarter. Vanguard Group Inc. boosted its stake in ContraFect by 24.2% during the third quarter. Vanguard Group Inc. now owns 2,634,428 shares of the biotechnology company’s stock worth $5,454,000 after acquiring an additional 512,940 shares in the last quarter. Federated Investors Inc. PA boosted its stake in ContraFect by 6.8% during the third quarter. Federated Investors Inc. PA now owns 6,407,500 shares of the biotechnology company’s stock worth $13,264,000 after acquiring an additional 407,500 shares in the last quarter. Finally, Vanguard Group Inc boosted its stake in ContraFect by 24.2% during the third quarter. Vanguard Group Inc now owns 2,634,428 shares of the biotechnology company’s stock worth $5,454,000 after acquiring an additional 512,940 shares in the last quarter. 55.54% of the stock is currently owned by institutional investors.

ContraFect Company Profile

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that is in Phase II human clinical trials for the treatment of Staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Read More: What is the QQQ ETF?

Get a free copy of the Zacks research report on ContraFect (CFRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ContraFect (NASDAQ:CFRX)

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply